Telco International

Telcon RF Pharmaceutical is a South Korean biotechnology company that successfully transitioned from its origins in telecommunications components to become a significant player in drug development. The company operates primarily through strategic investments and licensing agreements with global biopharmaceutical firms, most notably Humanigen and Abion. Its lead programs include lenzilumab, a monoclonal antibody targeting GM-CSF for the treatment of COVID-19 and other inflammatory conditions, and ABN401, a small molecule c-MET inhibitor for various solid tumors. Telcon RF Pharmaceutical focuses on high-unmet-need areas such as rare diseases, oncology, and infectious diseases, leveraging its international partnerships to advance clinical-stage assets in the Asian market.